Clinical trials: Covid19 Immunology
COVID-19, Acute Respiratory Failure
COVID Cohort Study
The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course.
- Trial name
- NCT04393155
- Testing
- COVID-19+ observational
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
COVID-19, Immunologic Factors
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
A two-stage trial will involve healthy volunteers. The first stage is open trial, and the second stage is a double-blind trial with randomization of volunteers into three groups.
- Conditions
- COVID-19, Immunologic Factors, Coronavirus Infections, Respiratory Tract Infections
- Trial name
- NCT05156723
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 3 sites in Russia
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Covid19
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subsequent exposure.
- Trial name
- NCT04892797
- Testing
- Covid-19+ observational
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
Rheumatic Disease, HIV Infections
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
Patients with chronic rheumatic diseases (such as systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], ankylosing spondylitis [AS], juvenile idiopathic arthritis [JIA], poly/dermatomyositis [PM/DM], systemic sclerosis…
- Conditions
- Rheumatic Disease, HIV Infections, AIDS, Safety Issues
- Trial name
- CoronavRheum (NCT04754698)
- Testing
- CoronaVac
- Where
- Brazil
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Covid19
COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes
This is a prospective cohort study of pregnant patients at an urban academic center diagnosed with perinatal COVID-19 infection, followed up to 6 weeks postpartum.
- Trial name
- COVID-PRICE (NCT04659759)
- Testing
- COVID-19 exposure, COVID-19 vaccine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Thomas Jefferson University
Covid19
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives)…
- Trial name
- Ta1 (NCT04487444)
- Testing
- Thymalfasin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rhode Island Hospital
COVID-19
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote…
- Trial name
- REMOTE (NCT06776367)
- Testing
- Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens
- Where
- 16 sites in United States
- Volunteers
- 1,753 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
HIV Seropositivity, Immunodeficiency
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional…
- Conditions
- HIV Seropositivity, Immunodeficiency, Vaccination Reaction, Covid19
- Trial name
- NCT05672654
- Testing
- Blood draw
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Pediatric Respiratory Diseases, COVID
COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology
Prospective cohort study of COVID-19 infection among children in Norway.
- Conditions
- Pediatric Respiratory Diseases, COVID, Fatigue Post Viral
- Trial name
- NCT04335773
- Where
- Norway
- Volunteers
- 350 people
- Sponsor
- University Hospital, Akershus
Primary Immune Deficiency, COVID
COVID-19 in PID Survey
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals.
- Trial name
- COPID19 (NCT04459689)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Imagine Institute
COVID-19, Vaccine Reaction
Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination
The vaccination campaign in France began in early 2021 and was declared mandatory for all French people in July 2021. The efficacy of COVID-19 vaccines has since been widely demonstrated, as well as their safety, and now 60% of…
- Trial name
- COVIBOOST (NCT05124171)
- Testing
- BNT162b2, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
- Where
- France
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Respiratory Syncytial Virus Infections, Immunocompromised Host
RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults
Respiratory syncytial virus (RSV), influenza, and SARS-CoV-2 are common respiratory viruses. In healthy adults they usually cause mild, cold-like illness, but in people whose immune system is severely weakened - such as people…
- Conditions
- Respiratory Syncytial Virus Infections, Immunocompromised Host, Influenza, COVID - 19
- Trial name
- NCT07816471
- Volunteers
- 350 people
- Sponsor
- Hospital Italiano de Buenos Aires
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV Infections
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV
This is a prospective, non-randomized observational study to examine SARS-CoV-2 vaccine immunogenicity, immune activation and HIV reservoirs in people with HIV infection in comparison with HIV-negative individuals, in those aged…
- Trial name
- NCT06731127
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Covid19
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection
AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata…
- Trial name
- AntiCov-220 (NCT05043324)
- Testing
- AntiCov-220
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Nguyen Thi Trieu, MD
HIV Infections, Tuberculosis Infection
European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol
Across Europe and worldwide, there are many studies following groups (cohorts) of children living with human immunodeficiency virus (HIV) and other infections over time, to monitor their long-term health.
- Conditions
- HIV Infections, Tuberculosis Infection, Hepatitis C, Covid19
- Trial name
- EPPICC (NCT04677842)
- Testing
- ART Therapy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Lymphopenia, Covid19
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19
Background: Lymphopenia is reported to be associated with the severity of disease progression in COVID-19. Low lymphocyte count is also associated with increasing age.
- Conditions
- Lymphopenia, Covid19, Older People
- Trial name
- NCT04800731
- Testing
- observation no intervention
- Where
- Belgium
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Lymphopenia
Etiology of Lymphopenia in Covid19 Infection
Study of the cause of lymphopenia in Covid19 viral infection will be done in 3 cohorts. First cohort will be patients asymptomatic or with mild symptoms. Second cohort will be patients with severe illness and admitted to ICU.
- Trial name
- NCT04404608
- Testing
- Complete blood picture, bone marrow aspiration cytology
- Where
- Egypt
- Volunteers
- 172 people
- Sponsor
- Dr Medhat Khafagy
HIV Infections
COVID-19 Prevalence in HIV-infected Patients
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them…
- Trial name
- SeCoVIHA (NCT04515225)
- Testing
- Blood Sample
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Cardiovascular Risk Factor, Burnout
Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi
The main objective of our project is to investigate the evolution of psychosocial, cardiovascular and immune markers in healthcare with different levels of exposure to the COVID-19 pandemic.
- Conditions
- Cardiovascular Risk Factor, Burnout, Immune Deficiency
- Trial name
- NCT04422418
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 200 people
- Sponsor
- Khalifa University for Science and Technology